Filing Flows › Zomedica (ZOMDF) › Q2 2026
Zomedica (ZOMDF) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Zomedica (ZOMDF) reported revenue of $9.5M for the second quarter 2026 (Q2 2026), +37% from a year earlier and +8% from the quarter before. Operating margin was -42.9%, net loss $3.8M (39.6% of revenue).
Zomedica, Q2 2026: revenue $9.5M (+37% year over year), operating margin -42.9%, net loss $3.8M, operating cash flow −$2.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.5M | +8% | +37% |
| Operating profit | −$4.1M | — | — |
| Net earnings | −$3.8M | — | — |
| Operating cash flow | −$2.6M | — | — |
What changed
Revenue was $9.5M in Q2 2026, up 37% year over year and up 8% from the previous quarter. Consumables was the largest line at 70% of revenue. Consumables added $1.4M year over year (up 26%), 53% of the total change.
Gross margin was 63.5%, down 3.5 points from Q2 2025. Operating costs exceeded revenue by $4.1M, an operating margin of -42.9%. Operating expenses fell 20% while revenue rose 37%. The quarter ended with a net loss of $3.8M, narrower than the previous quarter's $4.5M loss.
Operating cash flow was −$2.6M. Non-cash charges added back $1.8M of depreciation and amortization and $69K of share-based compensation. Working capital and other items used $698K. Capital expenditures of $92K exceeded it, leaving free cash flow of −$2.6M.
Questions
What was Zomedica's revenue in the second quarter 2026?
Zomedica (ZOMDF) reported revenue of $9.5M for the second quarter 2026 (Q2 2026), +37% from a year earlier and +8% from the quarter before.
Was Zomedica profitable in the second quarter 2026?
Operating loss was $4.1M (-42.9% of revenue) and net loss $3.8M.
Source: Zomedica 10-Q on SEC EDGAR.